Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.

Clinical Pharmacokinetics of Metformin

Abstract

Metformin is widely used for the treatment of type 2 diabetes mellitus. It is a biguanide developed from galegine, a guanidine derivative found in Galega officinalis (French lilac). Chemically, it is a hydrophilic base which exists at physiological pH as the cationic species (>99.9%). Consequently, its passive diffusion through cell membranes should be very limited. The mean ± SD fractional oral bioavailability (F) of metformin is 55 ± 16%. It is absorbed predominately from the small intestine. Metformin is excreted unchanged in urine. The elimination half-life (t(½)) of metformin during multiple dosages in patients with good renal function is approximately 5 hours. From published data on the pharmacokinetics of metformin, the population mean of its clearances were calculated. The population mean renal clearance (CL(R)) and apparent total clearance after oral administration (CL/F) of metformin were estimated to be 510 ± 130 mL/min and 1140 ± 330 mL/min, respectively, in healthy subjects and diabetic patients with good renal function. Over a range of renal function, the population mean values of CL(R) and CL/F of metformin are 4.3 ± 1.5 and 10.7 ± 3.5 times as great, respectively, as the clearance of creatinine (CL(CR)). As the CL(R) and CL/F decrease approximately in proportion to CL(CR), the dosage of metformin should be reduced in patients with renal impairment in proportion to the reduced CL(CR). The oral absorption, hepatic uptake and renal excretion of metformin are mediated very largely by organic cation transporters (OCTs). An intron variant of OCT1 (single nucleotide polymorphism [SNP] rs622342) has been associated with a decreased effect on blood glucose in heterozygotes and a lack of effect of metformin on plasma glucose in homozygotes. An intron variant of multidrug and toxin extrusion transporter [MATE1] (G>A, SNP rs2289669) has also been associated with a small increase in antihyperglycaemic effect of metformin. Overall, the effect of structural variants of OCTs and other cation transporters on the pharmacokinetics of metformin appears small and the subsequent effects on clinical response are also limited. However, intersubject differences in the levels of expression of OCT1 and OCT3 in the liver are very large and may contribute more to the variations in the hepatic uptake and clinical effect of metformin. Lactic acidosis is the feared adverse effect of the biguanide drugs but its incidence is very low in patients treated with metformin. We suggest that the mean plasma concentrations of metformin over a dosage interval be maintained below 2.5 mg/L in order to minimize the development of this adverse effect.

Overview

Integrity signals

Registry

Crossref · 10.2165/11534750-000000000-00000

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 99 references

Research works printed but not linked: 5

  1. Noel, 1979, Res Clin For, 1, 35
  2. Tzvetkov, 2009, Clin Pharmacol Ther, 86, 299, 10.1038/clpt.2009.92 · DOI · Paper page
  3. Salpeter, 2010, Cochrane Database Syst Rev, &NA;, CD002967
  4. Bruijstens, 2008, Neth J Med, 66, 185
  5. Marchetti, 1990, Diabetes Metab, 16, 473

Cited by

See all 1,318

Metadata

Authors
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., Ray, J. E., Timmins, P., & Williams, K. M.
Affiliations
  • UNSW Sydney (AU)
  • Flinders Medical Centre (AU)
  • St Vincent's Hospital Sydney (AU)
  • Garvan Institute of Medical Research (AU)
  • The University of Queensland (AU)
  • Bristol-Myers Squibb (United Kingdom) (GB)
Corresponding author
Graham, Garry G.
Venue
Clinical Pharmacokinetics
Published
2011-02
Volume
50
Issue
2
Pages
81-98
ISSN
0312-5963 (ISSN-L)
OpenAlex
W2020474316
Cited by
1,318
References
99
Citations by year
2026: 81 · 2025: 87 · 2024: 98 · 2023: 95 · 2022: 103 · 2021: 122 · 2020: 95 · 2019: 83 · 2018: 95 · 2017: 80 · 2016: 86 · 2015: 83 · 2014: 76 · 2013: 59 · 2012: 46
FWCI
8.75
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Pharmacokinetics (publishedVersion)
  • PubMed (publishedVersion)
Funders
Bristol-Myers Squibb
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
metformin, pharmacokinetics, type 2 diabetes, biguanides, renal clearance, organic cation transporters, OCT1, OCT3, MATE1, renal dysfunction, dose adjustment, single nucleotide polymorphisms, drug absorption, elimination half-life, hypoglycemic effect, renal excretion, hepatic uptake, Galega officinalis
MeSH terms
Administration, Oral, Biological Availability, Blood Glucose, Diabetes Mellitus, Type 2, Half-Life, Humans, Hypoglycemic Agents, Injections, Intravenous, Metformin, Polymorphism, Single Nucleotide, Organic Cation Transport Proteins, Renal Insufficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Pharmacokinetics of Metformin. https://app.cochat.ai/papers/10.2165/11534750-000000000-00000
The paper
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., Ray, J. E., Timmins, P., & Williams, K. M. (2011). Clinical Pharmacokinetics of Metformin. Clinical Pharmacokinetics. https://doi.org/10.2165/11534750-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.